文献速递乳腺癌

21基因复发分数对雌激素受体阳性、人表皮生长因子受体2阴性及淋巴结阴性早期乳腺癌患者化疗决策的影响

[Effect of 21-gene recurrence score on chemotherapy decisions for patients with estrogen receptor-positive, epidermal growth factor receptor 2-negative and lymph node-negative early stage-breast cancer].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2017-01-01

研究纳入148例ER阳性、HER-2阴性、淋巴结阴性早期乳腺癌患者,在知晓21基因复发分数(RS)前后经多学科讨论制定辅助治疗方案。知晓RS后26例(17.6%)化疗决策改变,其中9例免于化疗、16例由不建议化疗改为化疗、1例化疗方案改变。多因素分析显示年龄、组织学分级和RS为化疗决策的独立影响因素(均P<0.05)。

要点

  • 知晓21基因RS后,148例中26例(17.6%)辅助化疗决策发生改变。
  • 26例决策改变者中,9例免于化疗,16例由不建议化疗改为化疗,1例化疗方案改变。
  • 年龄、组织学分级和21基因RS为辅助化疗决策的独立影响因素(均P<0.05)。

核心结论

  • 21基因复发分数可影响ER阳性、HER-2阴性和淋巴结阴性早期乳腺癌患者辅助化疗决策的制订。

研究设计与样本

  • 收集2015年1月至2015年10月在上海交通大学医学院附属瑞金医院行21基因检测的148例ER阳性、HER-2阴性、淋巴结阴性早期乳腺癌患者的临床病理资料。
  • 患者在21基因检测前后行多学科讨论制订辅助治疗方案,分析21基因RS及其他影响因素对辅助化疗决策的作用。

主要发现

  • 知晓21基因RS结果后,148例中26例(17.6%)患者的化疗决策发生改变。
  • 26例决策改变者中,9例因21基因RS而免于化疗,16例由不建议化疗改为化疗,1例化疗方案发生改变。
  • 多因素分析显示,年龄、组织学分级和21基因RS为影响辅助化疗决策的独立因素(均P<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the effect of 21-gene recurrence score on adjuvant chemotherapy decisions for patients with estrogen receptor (ER)-positive, epidermal growth factor receptor 2 (HER-2)-negative and lymph node (LN)-negative early stage-breast cancer. Methods: One hundred and forty-eight patients with ER+ , HER-2- and LN- early stage breast cancer were recruited in the Ruijin hospital, Shanghai Jiao Tong University School of Medicine. The 21-gene recurrence score (RS)assay was performed and systemic therapeutic decisions were made before and after knowing the RS results under multidisciplinary discussion. The effects of RS assay and the other influential factors on adjuvant chemotherapy decision were further analyzed. Results: After knowing the RS results, treatment decisions were changed in 26 out of 148 patients(17.6%). Among them, 9 out of 26 patients were not recommended for chemotherapy; 16 of 26 had treatment recommendation changed to chemotherapy, and chemotherapy regimen was changed in the last one patient. Multivariate analysis showed that RS, age and histological grade were independent factors of decision-making for adjuvant chemotherapy. Conclusion: Our results suggest that 21-gene recurrence score significantly influences decision making for adjuvant chemotherapy in patients with ER+ , HER-2- and LN- early stage breast cancer. 目的: 探讨21基因复发分数(RS)对雌激素受体(ER)阳性、人表皮生长因子受体2(HER-2)阴性和腋窝淋巴结(LN)阴性早期乳腺癌患者辅助化疗决策的影响。 方法: 收集2015年1月至2015年10月行21基因检测、在21基因检测前后行多学科讨论制订辅助治疗方案的148例ER(+)HER-2(-) LN(-)早期乳腺癌患者的临床病理资料,研究21基因RS对辅助化疗决策的影响。 结果: 21基因检测RS使26例(17.6%)患者的化疗决策发生改变,其中9例患者因21基因检测RS而免于化疗,16例患者由不建议化疗改为化疗,1例患者化疗方案发生改变。多因素分析显示,年龄、组织学分级和21基因RS为影响ER(+)HER-2(-)LN(-)早期乳腺癌患者化疗决策的独立因素(均P<0.05)。 结论: 21基因RS可影响ER(+)HER-2(-)LN(-)早期乳腺癌患者辅助化疗决策的制订。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Mao Y, Chen XS, Liang Y, et al. [Effect of 21-gene recurrence score on chemotherapy decisions for patients with estrogen receptor-positive, epidermal growth factor receptor 2-negative and lymph node-negative early stage-breast cancer]. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 28728295. doi:10.3760/cma.j.issn.0253-3766.2017.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。